A Pilot Study of Rosiglitazone in Patients With Incurable Differentiated Thyroid Cancer
- Determine complete response in patients with locoregionally extensive or metastatic
differentiated thyroid cancer treated with rosiglitazone.
- Compare the long-term response of patients treated with this drug with historical
- Determine the toxicity profile of this drug in these patients.
- Determine the presence/persistence of tumor in patients treated with this drug.
- Determine the quality of life of patients treated with this drug.
- Determine overall survival of patients treated with this drug.
OUTLINE: This is a pilot study.
Patients receive oral rosiglitazone once daily on weeks 1-8. Patients also receive oral
liothyronine sodium twice daily on weeks 1-6 in preparation for radioactive iodine scan.
Treatment continues in the absence of disease progression or unacceptable toxicity. At week
8, all patients undergo whole body radioactive iodine scan followed by a treatment dose of
radioiodine to assess radioiodine uptake by tumor.
Quality of life is assessed at baseline and at the end of study treatment.
Patients are followed at 2 weeks, 1, 4, and 10 months, and then every 6 months for 1 year.
PROJECTED ACCRUAL: A total of 20-25 patients will be accrued for this study.
Primary Purpose: Treatment
Radioiodine uptake and thyroglobulin level at 6 months and 1 year
Electron Kebebew, MD
University of California, San Francisco
United States: Federal Government
|UCSF Helen Diller Family Comprehensive Cancer Center||San Francisco, California 94115|